Stay updated with breaking news from Study Director. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced two...
In this study we have 300 patients with 47 different diseases subject to 7 experimental treatments among 3 treatment groups and no control group. What could possibly go right?
Toronto, ON (PRWEB) November 03, 2021 -- The Extended One Generation Reproductive Toxicity Study (EOGRTS, EU B.56, OECD TG 443) has been the information
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic...
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic...